MCID: OST115
MIFTS: 42

Osteonecrosis of the Jaw

Categories: Bone diseases, Rare diseases, Oral diseases

Aliases & Classifications for Osteonecrosis of the Jaw

MalaCards integrated aliases for Osteonecrosis of the Jaw:

Name: Osteonecrosis of the Jaw 59

Classifications:



External Ids:

Orphanet 59 ORPHA399293
UMLS via Orphanet 74 C2711248
ICD10 via Orphanet 34 K10.2

Summaries for Osteonecrosis of the Jaw

MalaCards based summary : Osteonecrosis of the Jaw is related to osteonecrosis and arthritis. An important gene associated with Osteonecrosis of the Jaw is CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8), and among its related pathways/superpathways are Allograft rejection and HTLV-I infection. The drugs Zoledronic acid and Alendronate have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and bone marrow, and related phenotype is renal/urinary system.

Wikipedia : 76 Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws (the... more...

Related Diseases for Osteonecrosis of the Jaw

Diseases related to Osteonecrosis of the Jaw via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 32.3 CYP2C8 FDPS VEGFA
2 arthritis 30.1 HLA-DQB1 HLA-DRB1 IL17A
3 rheumatoid arthritis 29.8 HLA-DQB1 HLA-DRB1 IL17A VEGFA
4 periodontal disease 29.8 DEFB1 DEFB4A IL17A
5 central nervous system vasculitis 10.5 HLA-DRB1 IL17A
6 limbic encephalitis with lgi1 antibodies 10.5 HLA-DQB1 HLA-DRB1
7 cystic echinococcosis 10.5 HLA-DRB1 IL17A
8 ischemic bone disease 10.5 FDPS VEGFA
9 metal allergy 10.5 HLA-DQB1 HLA-DRB1
10 focal epithelial hyperplasia 10.5 HLA-DQB1 HLA-DRB1
11 hypersomnia 10.5 HLA-DQB1 HLA-DRB1
12 lichen planopilaris 10.5 HLA-DQB1 HLA-DRB1
13 type ii mixed cryoglobulinemia 10.5 HLA-DQB1 HLA-DRB1
14 beryllium disease 10.5 HLA-DQB1 HLA-DRB1
15 recurrent respiratory papillomatosis 10.5 HLA-DQB1 HLA-DRB1
16 autoimmune pancreatitis 10.5 HLA-DQB1 HLA-DRB1
17 chronic beryllium disease 10.5 HLA-DQB1 HLA-DRB1
18 pityriasis rosea 10.5 HLA-DQB1 HLA-DRB1
19 lichen sclerosus 10.5 HLA-DQB1 HLA-DRB1
20 whipple disease 10.4 HLA-DQB1 HLA-DRB1
21 acute disseminated encephalomyelitis 10.4 HLA-DQB1 HLA-DRB1
22 pediatric multiple sclerosis 10.4 HLA-DQB1 HLA-DRB1
23 osteoporosis 10.4
24 myeloma, multiple 10.4
25 idiopathic bronchiectasis 10.4 HLA-DQB1 HLA-DRB1
26 peanut allergy 10.4 HLA-DQB1 HLA-DRB1
27 hemorrhagic fever with renal syndrome 10.4 HLA-DRB1 SEMA4D
28 oligoarticular juvenile idiopathic arthritis 10.3 HLA-DQB1 HLA-DRB1
29 severe hemophilia a 10.3 HLA-DQB1 HLA-DRB1
30 neuromyelitis optica 10.3 HLA-DRB1 IL17A
31 endophthalmitis 10.3 DEFB1 VEGFA
32 juvenile nasopharyngeal angiofibroma 10.3 CYP19A1 VEGFA
33 ocular cicatricial pemphigoid 10.2 HLA-DQB1 HLA-DRB1
34 periodontitis 10.2
35 prostatitis 10.2
36 geographic tongue 10.2 HLA-DQB1 HLA-DRB1 VEGFA
37 panuveitis 10.2 HLA-DQB1 HLA-DRB1 IL17A
38 vogt-koyanagi-harada disease 10.2 HLA-DQB1 HLA-DRB1 IL17A
39 breast cancer 10.2
40 prostate cancer 10.2
41 corneal abscess 10.1 DEFB1 DEFB4A
42 osteomyelitis 10.1
43 endotheliitis 10.1
44 paraneoplastic pemphigus 10.1 HLA-DQB1 HLA-DRB1
45 thrombophilia 10.0
46 vulvovaginal candidiasis 10.0 DEFB1 DEFB4A
47 echinococcosis 10.0 HLA-DRB1 IL17A
48 oral candidiasis 10.0 DEFB1 DEFB4A
49 bone disease 10.0
50 fibrous dysplasia 10.0

Graphical network of the top 20 diseases related to Osteonecrosis of the Jaw:



Diseases related to Osteonecrosis of the Jaw

Symptoms & Phenotypes for Osteonecrosis of the Jaw

MGI Mouse Phenotypes related to Osteonecrosis of the Jaw:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.02 CYP19A1 HLA-DQB1 IL17A SEMA4D VEGFA

Drugs & Therapeutics for Osteonecrosis of the Jaw

Drugs for Osteonecrosis of the Jaw (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
2
Alendronate Approved Phase 4,Phase 2 121268-17-5, 66376-36-1 2088
3 Diphosphonates Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Hormones Phase 4
6
Gemcitabine Approved Phase 3 95058-81-4 60750
7
Denosumab Approved Phase 3,Phase 1,Phase 2 615258-40-7
8
Docetaxel Approved, Investigational Phase 3,Phase 2 114977-28-5 148124
9
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
10
Tocopherol Approved, Investigational, Nutraceutical Phase 3 1406-66-2 14986
11
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
12 Mitogens Phase 2, Phase 3,Not Applicable
13 Micronutrients Phase 3,Phase 2
14 Trace Elements Phase 3,Phase 2
15 Vitamins Phase 3,Phase 2
16 Tocopherols Phase 3
17 Tocotrienols Phase 3
18 Vasodilator Agents Phase 3
19 Phosphodiesterase Inhibitors Phase 3
20 Platelet Aggregation Inhibitors Phase 3
21 Antioxidants Phase 3
22 Protective Agents Phase 3
23 Radiation-Protective Agents Phase 3
24 Tocotrienol Investigational, Nutraceutical Phase 3 6829-55-6
25
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
26
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
27
Calcium Carbonate Approved, Investigational Phase 2 471-34-1
28
Teriparatide Approved, Investigational Phase 2 52232-67-4 16133850
29
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
30
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
31
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
32
Doxil Approved June 1999 Phase 2 31703
33 Anti-Bacterial Agents Phase 2,Not Applicable
34 Antibiotics, Antitubercular Phase 2,Not Applicable
35 Alkylating Agents Phase 2
36 Gastrointestinal Agents Phase 2,Phase 1
37 Topoisomerase Inhibitors Phase 2
38 Antacids Phase 2
39 Ergocalciferols Phase 2
40 Immunosuppressive Agents Phase 2
41 Anti-Ulcer Agents Phase 2
42 Antirheumatic Agents Phase 2
43 Antimitotic Agents Phase 2
44 Calcium, Dietary Phase 2
45 Antineoplastic Agents, Alkylating Phase 2
46 Antibodies Phase 1, Phase 2
47 Immunoglobulins Phase 1, Phase 2
48 Antibodies, Monoclonal Phase 1, Phase 2
49 Vitamin D2 Nutraceutical Phase 2
50 Calciferol Nutraceutical Phase 2

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
2 Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study Completed NCT02139007 Phase 4 Alendronate
3 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
4 Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis Completed NCT00523341 Phase 3
5 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
6 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ) Recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
7 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
8 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Active, not recruiting NCT00869206 Phase 3 zoledronic acid
9 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw Not yet recruiting NCT03390777 Phase 2, Phase 3
10 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed NCT00996801 Phase 2 MK-5442;Placebo to MK-5442;Alendronate Sodium;Vitamin D3;Calcium carbonate;Placebo to Alendronate
11 Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers Completed NCT01367288 Phase 2 Zometa + Neoadjuvant therapy;Neoadjuvant therapy
12 The Efficacy of Denosumab in Active Crohn's Disease Recruiting NCT02321280 Phase 1, Phase 2 Denosumab
13 Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury Previously Treated With Teriparatide Active, not recruiting NCT02195895 Phase 2 Alendronate
14 Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates Completed NCT00462098 Phase 1
15 Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis Recruiting NCT02566681 Phase 1
16 Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer Terminated NCT00892242 Phase 1 Zoledronic acid
17 Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay Unknown status NCT02218554 Not Applicable
18 Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction Unknown status NCT02198001 Not Applicable tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
19 CONDOR Study of Osteonecrosis of the Jaws (TMJ) Completed NCT01130389
20 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
21 Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Completed NCT01998607
22 DPBRN Retrospective Cohort Study of Osteonecrosis of the Jaw Completed NCT01201330
23 Proposal For The Development Of A Well Defined Database For Patients With Oral Bisphosphonate-Related Osteonecrosis Completed NCT00601068
24 Use of Topical Phenytoin in Bisphosphonate-related Osteonecrosis of the Mandible Completed NCT03269214 Not Applicable Topical Phenytoin 5%
25 Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging Completed NCT00592982
26 Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC Completed NCT01062503 Zoledronic acid
27 Medication-related Osteonecrosis of the Jaw (MRONJ) Registry Recruiting NCT02932501
28 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Recruiting NCT03418454
29 Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use Recruiting NCT01875458
30 Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction Recruiting NCT02661139
31 HBOT Late Radiation Tissue Injury Recruiting NCT02425215
32 Osteonecrosis of the Jaw (ONJ) Case Registry Active, not recruiting NCT01666106
33 Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid Active, not recruiting NCT01967160
34 S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases Active, not recruiting NCT00874211
35 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study Active, not recruiting NCT00858585
36 Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques Terminated NCT02747173
37 Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid Withdrawn NCT02069340 Not Applicable zoledronic acid

Search NIH Clinical Center for Osteonecrosis of the Jaw

Genetic Tests for Osteonecrosis of the Jaw

Anatomical Context for Osteonecrosis of the Jaw

MalaCards organs/tissues related to Osteonecrosis of the Jaw:

41
Bone, Prostate, Bone Marrow, Pancreas, Spinal Cord, T Cells, Endothelial

Publications for Osteonecrosis of the Jaw

Articles related to Osteonecrosis of the Jaw:

(show top 50) (show all 445)
# Title Authors Year
1
Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. ( 29955628 )
2018
2
Comment on: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29799056 )
2018
3
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )
2018
4
Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone. ( 29211870 )
2018
5
Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. ( 29870295 )
2018
6
Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. ( 29729428 )
2018
7
Early removal of sequestrum in patients affected by medication-related osteonecrosis of the jaw. ( 29422306 )
2018
8
Machine learning to predict the occurrence of bisphosphonate-related osteonecrosis of the jaw associated with dental extraction: A preliminary report. ( 29698784 )
2018
9
Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up. ( 29802059 )
2018
10
Microbial population changes in patients with medication-related osteonecrosis of the jaw treated with systemic antibiotics. ( 29325851 )
2018
11
Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review. ( 29747794 )
2018
12
Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-NaA^ve Patient: A Comprehensive Review of the Literature. ( 29850569 )
2018
13
Osteonecrosis of the Jaw in a Patient With Bone Metastatic Prostate Cancer After Long-term Bisphosphonate Treatment With Severe Deterioration Following Radium-223. ( 29861164 )
2018
14
Osteonecrosis of the jaws: a 14-year retrospective survey of hospital admissions. ( 29432652 )
2018
15
Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis. ( 29289789 )
2018
16
Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function. ( 29408511 )
2018
17
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? ( 29860712 )
2018
18
Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5A years of experience. ( 29948937 )
2018
19
Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw. ( 29857915 )
2018
20
Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis. ( 29713913 )
2018
21
Auto-Fluorescence and Histopathologic Evaluation of Medication-Related Osteonecrosis of the Jaws: Perspectives for Treatment. ( 29944562 )
2018
22
Authors' reply: Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. ( 29796683 )
2018
23
Medication-related osteonecrosis of the jaw, osteoradionecrosis, and osteomyelitis: A comparative histopathological study. ( 29723337 )
2018
24
The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. ( 29694412 )
2018
25
Duration of treatment with bisphosphonates at the time of osteonecrosis of the jaw onset in patients with rheumatoid arthritis. Review. ( 29325766 )
2018
26
Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings. ( 29952657 )
2018
27
Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care. ( 29932939 )
2018
28
New method of alloplastic reconstruction of the mandible after subtotal mandibulectomy for medication-related osteonecrosis of the jaw. ( 29751943 )
2018
29
Preventive dental management of osteonecrosis of the jaws related to zoledronic acid treatment. ( 29412504 )
2018
30
Patients' osteometabolic control improves the management of medication-related osteonecrosis of the jaw. ( 29249520 )
2018
31
Differences between osteoradionecrosis and medication-related osteonecrosis of the jaw. ( 29224060 )
2018
32
CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw. ( 29365278 )
2018
33
Efficacy of bovine lactoferrin in the post-surgical treatment of patients suffering from bisphosphonate-related osteonecrosis of the jaws: an open-label study. ( 29435826 )
2018
34
Treatment of pathologic fractures of the mandible in stage III medication-related osteonecrosis of the jaw-an observational study. ( 29885852 )
2018
35
WITHDROWN: Osteonecrosis of the jaw in patients traited by denosumab for malignant bone disease: Descriptive study on 9 cases ( 29680853 )
2018
36
Oral Methotrexate-related Lymphoproliferative Disease Presenting with Severe Osteonecrosis of the Jaw: A Case Report and Literature Review. ( 29225245 )
2018
37
Exposed necrotic bone in 183 patients with bisphosphonate-related osteonecrosis of the jaw: Associated clinical characteristics. ( 28809382 )
2017
38
Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates. ( 27918742 )
2017
39
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. ( 28604257 )
2017
40
Efficacy of the C-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review. ( 27876532 )
2017
41
Phosphate buffer-stabilized 0.1% chlorine dioxide oral rinse for managing medication-related osteonecrosis of the jaw. ( 29251459 )
2017
42
Identification of predisposing factors for osteonecrosis of the jaw after marginal mandibulectomy in the surgical management of oral squamous cell carcinoma. ( 29165823 )
2017
43
A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab. ( 29257800 )
2017
44
Can Autofluorescence Guide Surgeons in the Treatment of Medication-Related Osteonecrosis of the Jaw? A Prospective Feasibility Study. ( 29175416 )
2017
45
Axitinib-related osteonecrosis of the jaw. ( 28918879 )
2017
46
Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy. ( 28766109 )
2017
47
Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. ( 28941210 )
2017
48
Effect of different doses and durations of teriparatide therapy onA resolution of medication-related osteonecrosis of the jaw: AA randomized, controlled preclinical study in rats. ( 29395991 )
2017
49
A case of bisphosphonate-related osteonecrosis of the jaw with a particularly unfavourable course: a case report. ( 28875143 )
2017
50
Dental students' knowledge of medication-related osteonecrosis of the jaw. ( 29279671 )
2017

Variations for Osteonecrosis of the Jaw

Expression for Osteonecrosis of the Jaw

Search GEO for disease gene expression data for Osteonecrosis of the Jaw.

Pathways for Osteonecrosis of the Jaw

GO Terms for Osteonecrosis of the Jaw

Cellular components related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 DEFB1 DEFB103B DEFB4A IL17A SEMA4D VEGFA
2 clathrin-coated endocytic vesicle membrane GO:0030669 9.32 HLA-DQB1 HLA-DRB1
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.26 HLA-DQB1 HLA-DRB1
4 MHC class II protein complex GO:0042613 8.96 HLA-DQB1 HLA-DRB1
5 Golgi lumen GO:0005796 8.8 DEFB1 DEFB103B DEFB4A

Biological processes related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.65 DEFB1 DEFB103B DEFB4A
2 chemotaxis GO:0006935 9.63 DEFB1 DEFB103B DEFB4A
3 defense response GO:0006952 9.61 DEFB1 DEFB103B DEFB4A
4 defense response to Gram-positive bacterium GO:0050830 9.54 DEFB1 DEFB103B DEFB4A
5 antigen processing and presentation GO:0019882 9.51 HLA-DQB1 HLA-DRB1
6 defense response to Gram-negative bacterium GO:0050829 9.5 DEFB1 DEFB103B DEFB4A
7 killing of cells of other organism GO:0031640 9.49 DEFB103B DEFB4A
8 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.4 HLA-DQB1 HLA-DRB1
9 antimicrobial humoral response GO:0019730 9.33 DEFB1 DEFB103B DEFB4A
10 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.26 HLA-DQB1 HLA-DRB1
11 immune response GO:0006955 9.1 DEFB1 DEFB4A HLA-DQB1 HLA-DRB1 IL17A SEMA4D
12 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DQB1 HLA-DRB1

Molecular functions related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.4 HLA-DQB1 HLA-DRB1
2 steroid hydroxylase activity GO:0008395 9.37 CYP19A1 CYP2C8
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.32 CYP19A1 CYP2C8
4 aromatase activity GO:0070330 9.26 CYP19A1 CYP2C8
5 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
6 chemoattractant activity GO:0042056 9.13 DEFB103B DEFB4A VEGFA
7 CCR6 chemokine receptor binding GO:0031731 8.8 DEFB1 DEFB103B DEFB4A

Sources for Osteonecrosis of the Jaw

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....